Carlyle purchase of Resonetics stake values firm at $2.25 billion
Private equity firm becomes ‘meaningful shareholder’ in Nashua medical device manufacturer
Private equity investment firm Carlyle Group has bought a minority stake in Resonetics LLC, a Nashua-based medical device maker, in a deal that values the company at about $2.25 billion, according to an announcement last week from another equity firm, GTCR.
GTCR, which sold the stake, said the deal makes Carlyle a “meaningful shareholder” in Resonetics. It didn’t disclose details about the sale or its value. Also remaining a minority shareholder in Resonetics is Sverica Capital Management, which acquired the Nashua firm in 2014 before selling a majority interest to GTCR.
Founded in Nashua in 1987, Resonetics micro-manufactures components for complex medical devices to address diabetes, neurovascular diseases, and ophthalmological, interventional cardiology and structural heart concerns.
When Sverica bought the firm in 2014, Resonetics’ sole location was in Nashua, and it focused on polymer componentry for medical devices. After that, the company grew to 13 sites with 1,600 employees and expanded its capabilities into laser-machining metal components.
In November, Resonetics acquired Wisconsin-based Hudson Medical Innovations, a manufacturer of microfluidics, point-of-care diagnostics, biosensors and advanced wound care devices. It was
Resonetics’ 10th acquisition in the past five years.